Santen Pharmaceutical Co Ltd (Santen) manufactures and commercializes medicine for eye care, including eye drops and ointments.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Santen's R&D activities are focused on developing innovative medicines for the treatment of unmet medical needs in ophthalmology worldwide. The company’s pipeline products are aimed at the treatment of various ophthalmic indications such as dry eye, posterior uveitis, ocular hypertension, glaucoma, and myopia. The pipeline products of the company include, STN1011101, STN1011700, STN1012600, STN1013001, STN2000100, STN1014000 and STN1013900 for treatment related to glaucoma and the ocular hypertension; STN1007603 for vernal keratoconjunctivitis; STN1008903 and STN1014100 for dry eye; STN1010905 for meibomian gland dysfunction; STN1011402 for allergic conjunctivitis; and STN1010904 for treatment of Fuch’s endothelial corneal dystrophy. It also has STN1012700, STN1012701 and STN1013400 for treatment of various myopia in children; and STN1013600 for presbyopia. In FY2023, the company spent JPY28,297 million on its R&D, which as a percentage of its revenue stood at 10.1% YoY and grew 7.3% YoY. It carries out basic research, drug formulation research and non-clinical studies at its Nara R&D Center in Japan. It operates also R&D facilities in Japan, Finland, the US, China, where it conducts drug discovery and clinical development. The company offers grants to clinicians, scientists and academic institutions who are pursuing research on company’s medical devices, and compounds. Santen provides research support in therapeutic areas including glaucoma, retinal disorders, dry eye, corneal disorders, and other anterior segment conditions. It also works in partnership with other pharmaceutical companies, research institutes and universities to discover and launch new therapies for the treatment of various ophthalmological indications.